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Abstract
Amperometric glucose biosensors based on the immobilization of glucose oxidase (GOx) on Pt electrodes with electropolymer-
ized o-phenylenediamine (PPD) were implanted in the right striatum of freely-moving rats. Carbon paste electrodes for the
simultaneous monitoring of ascorbic acid (AA) and:or tissue O2 were implanted in the left striatum. A detailed in vivo
characterization of the Pt:PPD:GOx signal was carried out using various pharmacological manipulations. Confirmation that the
biosensor responded to changing glucose levels in brain extracellular fluid (ECF) was obtained by intraperitoneal (i.p.) injection
of insulin that caused a decrease in the Pt:PPD:GOx current, and local administion of glucose (1 mM) via an adjacent
microdialysis probe that resulted in an increase in the biosensor current. An insulin induced increase in tissue O2 in the brain was
also observed. Interference studies involved administering AA and subanaesthetic doses of ketamine i.p. Both resulted in increased
extracellular AA levels with ketamine also causing an increase in O2. No significant change in the Pt:PPD:GOx current was
observed in either case indicating that changes in O2 and AA, the principal endogenous interferents, have minimal effect on the
response of these first generation biosensors. Stability tests over a successive 5-day period revealed no significant change in
sensitivity. These in vivo results suggest reliable glucose monitoring in brain ECF. © 1998 Elsevier Science B.V.
Keywords: Glucose biosensor; Carbon paste electrodes; Brain extracellular glucose; Ascorbic acid; Oxygen; Ketamine; Real-time
monitoring; Freely-moving rats
1. Introduction
A number of biosensors have been developed for in
vivo measurement of biologically important compounds
which are either non-electroactive or only poorly elec-
troactive at analytically useful potentials (Turner et al.,
1987; Pfeiffer and Kerner, 1988; Pantano and Kuhr,
1995). The most thoroughly investigated is the glucose
biosensor incorporating the oxidoreductase enzyme,
glucose oxidase (GOx). GOx, isolated from Aspergillus
niger, has a high substrate specificity, a high turnover
rate and excellent stability, that make it ideally suited
for use in a biosensor (Wilson and Turner, 1992). This
enzyme catalyses the oxidation of D-glucose in the
presence of O2 producing H2O2:
bDglucoseGOx:FAD
Dgluconod lactoneGOx:FADH2 (1)
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GOx:FADH2O2GOx:FADH2O2 (2)
where FAD is the oxidised form of the prosthetic
group, flavin adenine dinucleotide.
Since the first report of a biosensor (for glucose) by
Clark and Lyons (1962) there has been extensive re-
search on the development and potential applications
of biosensors, principally for subcutaneous or intravas-
cular monitoring of glucose (Pfeiffer and Kerner, 1988).
This is because of the importance of glucose monitoring
in the disease diabetes mellitus and the fact that glucose
determination in various body fluids, such as blood,
plasma and urine, remains one of the most common
analysis carried out in clinical laboratories. However,
only a few such devices have been used in vivo in
neurochemical studies.With the exception of a report by
Boutelle et al. (1986) these have all been carried out in
anaesthetized animals and have all involved ampero-
metric enzyme-modified electrodes, predominantly for
glucose (Lowry et al., 1994a; Silver and Erecin˜ska,
1994; Lowry and Fillenz, 1996; Netchiporouk et al.,
1996; Lowry and Fillenz, 1997), with some recent re-
ports for glutamate (Albery et al., 1992; Hu et al., 1994;
Asai et al., 1996) and choline (Garguilo and Michael,
1993; Garguilo and Michael 1994). The small number
of such reports reflects the numerous difficulties associ-
ated with performing direct neurochemical measure-
ments in such a hostile and complex environment as
brain extracellular fluid (ECF). In addition to the obvi-
ous immunological response to the implanted sensor,
the ECF also contains surfactants (e.g. lipids), electrode
poisons (e.g. proteins) and potential electrocatalysts
(e.g. glutathione and ascorbic acid), all of which may
affect the performance (e.g. the stability and response)
of the implanted sensor (O’Neill, 1994). Other problems
include restriction of mass-transport to the electrode
surface by brain tissue, the biochemical effects of deple-
tion of a chemical species from this matrix and the
availability of suitable enzymes for the specific sub-
strates of interest. Therefore, in order for a biosensor to
operate reliably in brain ECF these and other factors
such as size, linear calibration range and response time
must be addressed in the design and development of the
sensor.
Recently, the groups of Zambonin (Malitesta et al.,
1990) and Yacynych (Sasso et al., 1990) have reported
H2O2-detecting biosensors based on the immobilisation
of GOx in electropolymerized poly(phenylenediamine)
films on Pt electrodes with properties (e.g. interference-
free, high enzyme activity and low response time) indi-
cating ideal suitability for detecting substrates in
biological fluids. Several groups, including ourselves,
have now used this technology to develop and charac-
terise biosensors for a variety of substrates (Bartlett and
Birkin, 1994; Dong, 1994; Lowry et al., 1994a; Friede-
mann et al., 1996). We have focused on the develop-
ment of a glucose sensor for applications in the
mammalian brain, as glucose is the primary energy
source for the brain and a constant supply is essential
to maintain normal cerebral function. A detailed in
vitro characterisation has been carried out; this sensor,
which utilises polymeric o-phenylenediamine (PPD),
has a fast response time, linearity over the relevant
concentration range, freedom from protein and lipid
fouling and minimal interference from endogenous spe-
cies such as AA and O2 over physiologically relevant
concentration ranges (Lowry et al., 1994a,b; Lowry and
O’Neill, 1994).
However, before any sensor can be used reliably in
vivo it is necessary to perform a detailed in vivo
characterisation to ensure the properties obtained in the
in vitro environment are maintained in the more com-
plex and hostile biological milieu. Thus, in the present
study we have implanted the Pt:PPD:GOx biosensor in
rat striatum and characterised the response in detail in
awake freely-moving animals in order to provide un-
equivocal proof of what is being detected.
2. Methodology
2.1. Chemicals and solutions
The enzyme glucose oxidase from Aspergillus niger
(EC 1.1.3.4, Grade I), was obtained from Boehringer
Mannheim, East Sussex, UK. The o-phenylenediamine
(free base), L-ascorbic acid (AA; A.C.S. reagent), ke-
tamine (hydrochloride) and insulin (from bovine pan-
creas) were from Sigma Chemical, Dorset, UK.
D( )-glucose (AnalaR grade) was obtained from BDH
Laboratory Supplies, Poole, UK. The NaCl, KC1,
NaH2PO4, NaOH, MgCl2 (all BDH, AnalaR grade)
and CaCl2 (Sigma) were used as supplied. Carbon paste
was prepared by thoroughly mixing 2.83 g of carbon
powder (UCP-1-M, Ultra Carbon, Bay City, MI) and
1.0 ml of silicone oil (Aldrich Chemical, Dorset, UK,
Catalogue No. 17563-3) (O’Neill et al., 1982).
Stock solutions of 1 M glucose were prepared, left
for 24 h at room temperature to allow equilibration of
the anomers and then stored at 4°C. All AA solutions
were prepared just before use because of their gradual
decomposition. Stock solutions of 100 mM AA were
prepared for in vitro calibrations. In in vivo experi-
ments solutions of AA (2 ml, 2 g:kg), insulin (1 ml, 15
U:kg), ketamine (1 ml, 50 mg:kg) and glucose (0.36 g in
2 ml) were administered intraperitoneally (i.p.). The pH
of the AA solutions was adjusted to between 6.5 and
7.0 using NaOH. Insulin solutions were prepared in a
phosphate buffered saline (PBS) solution, pH 7.4 (150
mM NaCl, 40 mM NaH2PO4 and 40 mM NaOH) and
sonicated with heating for :5 min to ensure complete
dissolution. Glucose solutions used in in vivo experi-
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ments were prepared in artificial cerebrospinal fluid
(aCSF: 147 mM NaCl, 4 mM KCl, 1.2 mM CaCl2 and
1 mM MgCl2) (de Boer et al., 1990) for microdialysis
experiments (1 mM) and in normal saline (NaCl 0.9%)
for i.p. injections (1 M). All solutions were prepared
using deoxygenated doubly distilled deionised water.
2.2. Working electrode preparation
Glucose biosensors were based on the immobilization
of GOx on Pt electrodes with the polymer PPD. Pt:
PPD:GOx disk electrodes were prepared from Teflon-
coated platinum:iridium (Pt:Ir 90%:10%) wire (125 mm
bare diameter, 160 mm coated diameter (5T), Advent
Research Materials, Suffolk, UK) following a previ-
ously reported procedure (Lowry et al., 1994a). Pt:
PPD:GOx cylinder electrodes were made from 5 cm
lengths of the same 5T wire. From each end : 5 mm
of the teflon insulation was carefully cut. The tip of the
wire and the end of the teflon insulation at one end
were then sealed under a microscope with epoxy glue to
produce a 4 mm active length of bare wire. A gold
electrical contact (Semat Technical, Herts, UK) was
soldered to the other end. In order to ensure good GOx
adsorption the exposed 4 mm of wire was then scored
repeatedly with a scalpel blade. GOx was immobilised
in PPD by potentiostatic electropolymenzation of the
o-phenylenediamine monomer (o-PD, 300 mM) follow-
ing a modified form of a previously reported procedure
(Lowry et al., 1994a). Briefly, a deoxygenated solution
of the monomer was prepared in PBS, pH 7.4. Elec-
trodes were left standing in this o-PD solution for 60
min and then transferred to an enzyme solution (3 mg
(850 U) GOx in 5 m l o-PD). When the enzyme was
visibly adsorbed (ca. 5–10 min, as indicated by a yellow
coating on the wire), the electrodes were transferred to
a plastic electrochemical cell (in house three-electrode
design) containing 10 ml of a freshly prepared o-PD
solution. The reference (saturated calomel electrode,
SCE) and auxiliary electrode (large Pt wire) were then
connected and the electropolymerization procedure
started by applying 650 mV to the Pt:PPD:GOx
electrodes. The polymerization was terminated after 15
min and the Pt:PPD:GOx electrodes were then rinsed
by immersion in PBS to remove loosely bound enzyme
and unreacted monomer. When not in use all Pt:PPD:
GOx electrodes were stored in PBS at 4°C. Carbon
paste disk electrodes (CPEs) were also made from 5 cm
lengths of 5T teflon-coated Pt:Ir wire following a previ-
ously described procedure (Lowry et al., 1997).
2.3. Microdialysis probe construction
Concentric microdialysis probes were constructed as
described previously (Demestre et al., 1997). The length
of the probe was 4 mm and the external diameter of the
sampling region of the probe was 300 mm. Before
implantation each probe was tested for leakages by
perfusing aCSF at 2 m l:min using a CMA 100 microdi-
alysis pump (CMA Microdialysis, Stockholm, Sweden).
2.4. In 6itro conditioning and characterisation of
Pt:PPD:GOx electrodes
Prior to implantation all Pt:PPD:GOx electrodes
were preconditioned in vitro by continuous recording
(see below) in 5 mM glucose over a 10 h period.
Electrodes were then calibrated in vitro for both glu-
cose (0–100 mM) and AA (0–1 mM) to ensure selectiv-
ity and linearity of response of the sensor for glucose
(Lowry and O’Neill, 1994). Calibrations were carried
out in a standard three-electrode glass electrochemical
cell. A SCE was used as the reference electrode and a
large silver wire, isolated in a compartment containing
PBS, served as the auxiliary electrode. To facilitate
mixing, solutions were bubbled with air (glucose;
RENA 102 air pump, RENA, France) or N2 (AA, BOC
Gases, Guildford, UK) for ca. 10 s following the addi-
tion of each aliquot. The current was then measured
when the solution was quiescent. The electrodes were
held at a constant potential of 700 mV, which is the
value generally used for H2O2 detection (Lowry et al.,
1994a). All calibrations were carried out at room tem-
perature with the exception of a series of experimental
measurements done at 37°C. These were made by plac-
ing the cell on a temperature regulated hot plate (9
2°C, Sigma) and monitoring the solution temperature
with a thermometer (Sigma) fixed permanently in the
solution as near as possible to the biosensor. In experi-
ments involving microdialysis, a characterized Pt:PPD:
GOx electrode was glued with epoxy to a microdialysis
probe ca. 1 h prior to implantation so that the 4 mm
active lengths of both probe and electrode were directly
aligned. Care was taken to ensure that the probe and
sensor were within 1 mm of each other.
2.5. Surgical procedures
Male Sprague-Dawley rats weighing 200–300 g were
anaesthetised, following published guidelines (Wolfen-
sohn and Lloyd, 1994), with a mixture of Hypnorm
(Janssen Pharmaceuticals, Oxford, UK), Hypnovel
(Roche Products, Herts, UK) and sterile water, mixed
1:1:2 and injected i.p. at a volume of 3.3 ml:kg, as
described previously (Fray et al., 1996; Lowry and
Fillenz, 1997). Electrodes were then implanted follow-
ing a previously described procedure (Lowry et al.,
1997); CPEs were implanted in the left striatum (coor-
dinates with the skull levelled between bregma and
lambda, were: A:P 1.0 from bregma, M:L 2.5 and
D:V 5.0 from dura (Paxinos and Watson, 1986)),
Pt:PPD:GOx electrodes in the right striatum (coordi-
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nates: A:P 1.0 from bregma, M:L 2.5 and D:V
8.5 from dura), and in experiments involving micro-
dialysis the combined Pt:PPD:GOx electrode and mi-
crodialysis probe (perfused with aCSF at 2 m l:min) was
implanted in the right striatum (coordinates: A:P 1.0
from bregma, M:L 2.5 and D:V 8.5 from dura). A
reference electrode (8T Ag wire, 200 mm bare diameter;
Advent Research Materials) was placed in the cortex,
an auxiliary electrode (8T Ag wire) placed between the
skull and dura and an earth wire (8T Ag wire) attached
to one of the support screws. The reference potential
provided by the bare Ag wire in brain tissue is very
similar to that of the SCE (O’Neill, 1993). The elec-
trodes and probe were fixed to the skull with dental
screws and dental acrylate (Associated Dental Products,
Swindon, UK). Surgery typically lasted 40 min and
anaesthesia was reversed by an i.p. injection of nalox-
one (0.1 mg:kg, Sigma). Post-operative analgesia was
provided in the form of a single injection (0.1 mg:kg,
s.c.) of Vetergesic (Reckitt and Colman Pharmaceuti-
cals, Hull, UK) given immediately following the
surgery. Animals were allowed to recover after surgery
and were assessed for good health according to pub-
lished guidelines (Morton and Griffiths, 1985) immedi-
ately after recovery from anaesthesia and at the
beginning of each day. This work was carried out under
licence in accordance with the Animals (Scientific Pro-
cedures) Act, 1986.
2.6. Instrumentation and software
A low-noise potentiostat (Biostat II, Electrochemical
and Medical Systems, Newbury, UK) was used in all
experiments. For constant potential amperometry
(CPA) experiments, either a Macintosh IIx computer or
a Mitac 486 PC was used with data acquisition carried
out using National Instruments (NI, National Instru-
ments, Austin, TX) multifunction data acquisition
boards: NB-MIO-16X (Macintosh) and AT-MIO-16
(PC). Further noise reduction was achieved by averag-
ing 75 (Mac) and 100 (PC) determinations to give one
data point every 2 s. For differential pulse amperome-
try (DPA) experiments, all data acquisition was carried
out on a Mitac 486 PC with data sampling carried out
at a rate of 250 determinations:pulse and averaged to
give one data point:pulse (Lowry et al., 1996). A com-
plete pulse sequence was carried out every 2 s. All
experiments were carried out using in house developed
software: PC (LabWindows, NI version 2.1); Macin-
tosh (LabVIEW, NI version 2.2.1). All analysis was
carried out using both in house developed software and
the commercial packages Igor Pro 2.0 (WaveMetrics,
OR) and Prism (GraphPad Software, CA). All data are
presented as mean9SEM. The significance of differ-
ences observed was estimated using the Student’s t-test
(two-tailed) for paired observations (StatView, Abacus
Concepts, CA), or the repeated measures ANOVA with
Tukey’s posthoc test.
Animal motor activity was recorded using a radar
based doppler shift motion detection unit (RS8960, RS
Components, Northants, UK; 10.7 GHz, wavelength
2.8 cm) connected to the Mitac PC via the NI AT-
MIO-16 data acquisition board. The meter was
modified with a closed end metal wave guide so that
ambulatory movements, grooming, feeding and drink-
ing registered, but not lesser movements such as breath-
ing (Berners, 1996).
2.7. Experimental conditions
Rats were housed in large plastic bowls (diameter ca.
50 cm), in a windowless room under a 12 h light:dark
cycle, lights coming on at 8 a.m., with free access to
water. Food was available ad libitum except for experi-
ments involving insulin where animals were fasted for
24 h prior to administration. All experiments were
carried out with the animal in its home bowl. Im-
planted electrodes were connected to the potentiostat
through a six-pin teflon socket and a flexible screened
six core cable which was mounted through a swivel
above the rat’s head (Semat Technical) at least 60 min
prior to the start of the first experiment each day. This
arrangement allowed free movement of the animal.
Once the background current for the Pt:PPD:GOx
electrode had stabilised (typically 30–45 min) experi-
ments were begun. The O2 and AA signal from the CPE
stabilised within 5–10 min. All signals were recorded at
2 s intervals. At the end of each day the animals were
disconnected from the recording equipment.
2.8. Voltammetric techniques in 6i6o
As with in vitro experiments, CPA at 700 mV
(versus implanted Ag reference electrode) was used for
H2O2 oxidation at the Pt:PPD:GOx electrodes in vivo.
Changes in O2 and AA at implanted CPEs were moni-
tored using either DPA or CPA. The DPA technique
allows the simultaneous monitoring of both species.
For O2 reduction, two equally sized cathodic pulses
were applied, the first from a resting potential at 150
to 350 mV that corresponds to the foot of the
reduction wave for O2 at lipid-modified CPEs and the
second from 350 to 550 mV that corresponds to
the peak of the reduction wave. Following the same
criterion, equally sized anodic pulses were then applied
from 150 to50 mV and from 50 to 250 mV
for AA oxidation. The difference in the current (DI)
sampled during these respective pulse pairs was calcu-
lated and changes in DI used as a measure of changes
in O2 and AA that have been shown to be interference
free (Lowry et al., 1996). In experiments involving
CPA, O2 was detected by holding the implanted CPE at
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the reduction potential of 550 mV (Lowry et al.,
1997). The potential for AA detection was chosen as
250 mV, which is just above the peak potential for
AA oxidation but below that for the onset of the
oxidation of other neurochemical species at implanted
CPEs (Boutelle et al., 1989). Post in vivo calibrations
for AA and O2 were carried out using the two tech-
niques. Calibrations for dissolved O2 were carried out
in N2 purged, air-saturated and O2-saturated solutions
where the concentrations of solution O2 were taken as
0, 200 (Bourdillon et al., 1982; Zhang and Wilson,
1993) and 1250 mM (Bourdillon et al., 1982), respec-
tively. AA calibrations were carried out in the range
0–1 mM.
3. Results and discussion
3.1. Effect of temperature on biosensor response
Temperature-dependence studies at GOx-modified
electrodes in phosphate buffer have indicated that the
glucose response may increase by between 20 (Shaolin
et al., 1991) and 60% (Fortier et al., 1990) in the range
25–37°C. Thus, before performing experiments in vivo
we first examined the effect of temperature on the
Pt:PPD:GOx signal since all our previous in vitro
experiments had been carried out at a thermostatically
controlled temperature of 25.090.5°C (Lowry et al.,
1994a; Lowry and O’Neill, 1994). Glucose calibrations
were therefore carried out at room (22.590.2°C) and
near physiological (37.690.2°C) temperatures in the
range 0–100 mM. The Vmax, calculated using a
modified Michaelis-Menten (Hill-type) equation (Lowry
et al., 1994a), 100 mM glucose and 1 mM glucose
responses were similar at both temperatures (n3):
Vmax, 127932 nA (22°C) and 127937 nA (37°C;
p\0.97); 100 mM, 122930 nA (22°C) and 117932
nA (37°C; p\0.50); 1 mM, 4.491.8 nA (22°C) and
6.790.6 nA (37°C; p\0.42); indicating that the
change in temperature from in vitro to in vivo condi-
tions will have minimal effect on the response of the
biosensor. This property may be due to the nature of
the PPD film which is a highly insulating thin (ca. 10
nm) polymer immobilising the GOx (diameter 8.6 nm)
close to the electrode surface and acting as an efficient
diffiusion barrier preventing glucose penetrating the
film but not preventing it reaching the active site and
producing H2O2 (Sasso et al., 1990). The detection
limit, defined as the analyte (glucose) concentration
yielding a signal equal to three times the standard
deviation of the background current, for these 4 mm
cylinder biosensors was calculated as 3.5390.48 mM
(n4).
3.2. Effect of insulin on biosensor response in 6i6o
In order to demonstrate that Pt:PPD:GOx sensors
respond to changes in glucose in brain ECF we began
the in vivo characterization by examining the effect of
insulin on the in vivo response. Insulin, which lowers
plasma glucose levels (Chen and Steger, 1993) and has
also been reported to lower brain ECF levels (Bhat-
tacharya and Saraswati 1991), was injected i.p. (15
U:kg) into freely-moving fasted rats implanted with a
glucose biosensor in the right striatum and a CPE in
the left striatum. The mean baseline glucose current
decreased by 0.6 90.1 nA (n4; pB0.01) 41911 min
after injection, representing a decrease in response of
1494% (Fig. 1, top). This period of minimum glucose
current lasted approximately 22910 min during which
the animals were inactive but responsive to external
stimuli suggesting that this dose of insulin did not
produce hypoglycaemic coma. There was then a grad-
ual return to baseline values or above during which the
animals ingested food and resumed activity.
Fig. 1. The effect of intraperitoneal injection of insulin (1 ml, 15
U:kg) on the Pt:PPD:GOx (top) and carbon paste electrode (CPE)
O2 (bottom) signals recorded simultaneously with bilaterally im-
planted sensors in the striatum of freely-moving rats. The tissue O2
levels at the CPEs were monitored using both differential pulse
amperometry and constant potential amperometry. Data (n4) are
normalised with the basal level before injection taken as 100%. The
hashed lines represent the SEM which is plotted at 12 min intervals
for clarity. Changes in response expressed in nanoamperes of current
are given in the text. See Section 3.2.
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Tissue O2 levels were recorded simultaneously at the
implanted CPEs using both DPA and CPA. Injection
of insulin caused a maximum increase in cathodic cur-
rent of 1897 nA (n4; pB0.05) above baseline at
63922 min. We have previously shown that both these
techniques can be used to monitor changes in tissue O2
in vivo during neuronal activation (Lowry et al., 1997).
However, typical baseline currents observed in vivo for
the DPA and CPA O2 signals are 748918 nA
(n3) and 4994 nA (n3), respectively. It is thus
not possible to calculate a percentage change in O2
concentration from the in vivo signal. However, post in
vivo calibrations of CPEs indicate that despite such
background currents there is no significant difference
(p\0.95, n5) in the sensitivity for O2 using the two
techniques: 3789136, n5 (DPA) and 3719
100, n5 (CPA). Therefore, using these calibrations
the increase in O2 observed with insulin corresponds to
a change in concentration of 68923 mM, n4 (Fig. 1,
bottom), which if one assumes a basal ECF concentra-
tion of 50 mM (Zimmerman and Wightman, 1991)
corresponds to an approximate doubling of the ECF
level.
These results suggest that Pt:PPD:GOx sensors re-
spond to changing glucose levels in the ECF. A fall in
brain glucose in animals given insulin has previously
been reported by several groups using GOx-modified
microelectrochemical sensors. Boutelle et al. (1986) ob-
served a similar decrease of :10% in awake freely-
moving animals with the same dose of insulin. Silver
and Erecin˜ska (1994) and Netchiporouk et al. (1996)
however both observed decreases of :80–90% of con-
trol. This difference may be due to a combination of
factors including the use of higher doses of insulin (25
and 40 U:kg, respectively) and the fact that both these
reports involved acute experiments on anaesthetized
animals where a decrease in the extracellular concentra-
tion of glucose would be expected (Fillenz and Lowry,
1997). An increase in brain O2 levels accompanying an
insulin induced fall in brain glucose has also been
reported by Silver and Erecin˜ska (1994). The different
time courses of changes in glucose and oxygen observed
with insulin suggest that changing O2 levels in vivo do
not influence the Pt:PPD:GOx signal supporting our
previously published in vitro work on O2 interference
(Lowry et al., 1994b). A more detailed investigation of
this type of interference is presented below (see Section
3.4).
3.3. Effect of glucose on biosensor response in 6i6o
Further evidence that Pt:PPD:GOx sensors respond
to glucose changes in the ECF may be obtained by
increasing the extracellular concentration of glucose.
This has previously been achieved using intraperitoneal
injections of glucose (Silver and Erecin˜ska, 1994;
Netchiporouk et al., 1996) or the hormone glucagon
(Netchiporouk et al., 1996), which counterbalances the
action of insulin in that it regulates the concentration of
blood glucose by increasing the break down of glycogen
stores (Stryer, 1988). However, the effect of glucagon
was found to produce only a small rise in ECF glucose
before triggering insulin release and a subsequent fall in
glucose to below basal levels (Netchiporouk et al.,
1996).
We examined the effect of injecting glucose (0.36 g in
2 ml i.p.) on the in vivo response of the implanted
biosensor in awake normoglycemic animals and found
no significant difference (p\0.46, n3) in the signal
before (12.591.1 nA, n3) and after (12.890.7 nA,
n3) injection. This is contrary to previous reports
where injection of similar doses resulted in increased
glucose levels (Silver and Erecin˜ska, 1994;
Netchiporouk et al., 1996). However, the animals used
in those experiments may have been more sensitive to
hyperglycemia since one of the reports involved injec-
tions during insulin induced hypoglycemia
(Netchiporouk et al., 1996) and both involved anaes-
thetics which lower ECF glucose (Fillenz and Lowry,
1997). In the only other report involving awake freely-
moving animals glucose was administered by infiusion
through a cannula placed next to the implanted sensor
(Boutelle et al., 1986) because i.p. injections failed to
produce an increase in the extracellular concentration
(Boutelle, M.G., personal communication). This and
our similar observation, agree with results where eleva-
tion of plasma glucose levels from 8 to 50 mM resulted
in only modest increases in CSF glucose, suggesting
control and carrier saturation (DiMattio and Streit-
man, 1988). Therefore, in order to increase ECF glu-
cose levels in the local environment of the Pt:PPD:GOx
sensor a microdialysis probe was combined with the
biosensor before implantation into the striatum. The
reason for this was two-fold in that not only does it
enable direct administration of glucose in the present
experiments it will also allow local infusion of drugs
(e.g. propranolol (Fray et al., 1996)) for future studies
of brain energy metabolism. Perfusion of a 1 mM
glucose solution through the dialysis probe at a flow
rate of 2 m l:min produced a maximum increase in
current of 2.390.6 nA (n5; pB0.02) from a mean
baseline of 17.093.7 nA. This represents a mean in-
crease of 1493% and provides corroborating evidence
that Pt:PPD:GOx sensors respond to changing glucose
levels in the ECF. A typical example of the effect of
such a perfusion on the current from an adjacent
Pt:PPD:GOx sensor is shown in Fig. 2.
3.4. Effect of oxygen on biosensor response in 6i6o
Pt:PPD:GOx sensors are ‘first generation’ devices
since they detect glucose by oxidising H2O2 formed
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Fig. 2. A typical example of the effect of perfusing glucose (1 mM in
aCSF) through a microdialysis probe on the current recorded with an
adjacent Pt:PPD:GOx sensor. The combined probe and sensor were
implanted in the right striatum of a freely-moving rat. The dark bar
represents the period of perfusion. See Section 3.3.
4.590.2 nA (4296 min; p\0.7). These results sup-
port our previous in vitro O2 interference studies
(Lowry et al., 1994b) and confirm that Pt:PPD:GOx
sensors are not affected by changes in O2 over physio-
logically relevant concentration ranges for the brain. A
similar lack of O2 interference has also been observed
by other groups; Asai et al. (1996) have used glutamate
oxidase and a dialysis electrode incorporating a PPD
coated Pt wire to monitor brain extracellular glutamate
during acute ischemia and found that the sensor oper-
ates reliably despite the lack of O2 around the dialysis
electrode and Garguilo and Michael (1994) have found
that the availability of O2 in brain ECF is sufficient for
Fig. 3. An example of the effect of a subanaesthetic intraperitoneal
injection of ketamine (50 mg:kg) on the carbon paste electrode (CPE)
O2 (A) and Pt:PPD:GOx (B) signals recorded simultaneously in the
striatum of freely-moving rats with bilaterally implanted sensors. The
tissue O2 was monitored using differential pulse amperometry and the
background current has been subtracted. Also shown is a record of
the motor activity (C) recorded over the same period with a radar-
based doppler shift motion detector. See Section 3.4.
from the reaction of O2, the natural cosubstrate for
GOx, with the reduced form of the enzyme (GOx:
FADH2) which is generated by reaction with glucose
(see reactions 1 and 2 above). We have previously
demonstrated in vitro that these biosensors respond to
glucose in O2-depleted (N2-saturated) solutions with a
sensitivity similar to that of air-saturated media (200
mM O2) (Bourdillon et al., 1982; Zhang and Wilson,
1993), suggesting that in brain tissue where the range of
O2 tension is 5–50 mM (Feng et al., 1988; Zimmerman
and Wightman, 1991), glucose monitoring should be
free of O2 interference (Lowry et al., 1994b).
To test the effect of changing O2 levels on the re-
sponse of the glucose biosensor in vivo we simulta-
neously recorded both Pt:PPD:GOx and CPE O2
signals before and after administration of the anaes-
thetic ketamine. Ketamine is a non-competitive antago-
nist of the glutamatergic N-methyl-D-aspartate
(NMDA) receptor (Jantzen, 1994; Lahti et al., 1995)
which causes an initial decrease in striatal tissue O2 and
regional cerebral blood flow (rCBF), followed, on re-
covery, by an increase in both variables to levels above
basal, which is accompanied by a period of intense
motor activity predominated by stereotypic head move-
ments (Lowry, J.P., unpublished observations). A typi-
cal example of the effect of a subanaesthetic ketamine
injection (50 mg:kg) on the Pt:PPD:GOx and O2 (CPE)
signals recorded simultaneously in the striatum of a
freely-moving rat is shown in Fig. 3, together with a
record of the motor activity for the same period. In
three experiments the average O2 current recorded us-
ing DPA increased to a maximum of 79918 nA (n3,
pB0.05) above baseline 3.290.8 min following injec-
tion and was still elevated at 4296 min (77925 nA),
whereas there was no significant change in the response
of the glucose biosensor over the same period: 4.790.3
nA (baseline), 4.790.3 nA (3.290.8 min; p\0.6) and
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reliable operation of choline sensors based on the im-
mobilisation of choline oxidase onto carbon fiber mi-
croelectrodes.
3.5. Effect of ascorbic acid on biosensor response in
6i6o
The principal endogenous electroactive interferent
affecting the application of electrochemical sensors in
brain ECF is the reducing agent AA, which exists in
anionic form at physiological pH (Youngblood, 1989)
and whose extracellular concentration has been esti-
mated at :500 mM (Miele and Fillenz, 1996). In order
to determine whether AA in brain ECF would interfere
with glucose detection using a Pt:PPD:GOx sensor we
simultaneously monitored AA concentration in the left
striatum with a CPE at a constant potential of 250
mV and the Pt:PPD:GOx current in the right striatum
following injection of a high dose (2 g:kg, i.p.) of AA.
The AA current increased from a mean baseline value
of 2.490.7 to 5.291.0 nA (n5; pB0.04) 1193 min
after injection. Since techniques such as CPA which
have long sampling times cause a significant depletion
of extracellular AA (Rice and Nicholson, 1995), it is
not possible to quantify the latter increase in current in
terms of concentration, however, this increase (for i.p.
injection) is substantially greater than the increases
observed using CPA during normal and stimulated
physiological activity (Boutelle et al., 1989). There was
no overall change in the response of the Pt:PPD:GOx
sensors during the same period: 3.190.9 nA to 3.09
0.9 (n5; p\0.25), clearly demonstrating that the
observed glucose signal is not affected by changes in
AA in vivo, even those greater than observed during
behavioural activation (Fig. 4).
We also monitored extracellular AA during the injec-
tion of subanaesthetic doses of ketamine using the DPA
technique, which, in addition to detecting changes in
O2, also enables simultaneous monitoring of AA in vivo
(Lowry et al., 1996). Injection of 50 mg:kg ketamine
i.p., which produced no change in the Pt:PPD:GOx
signal (see above), caused a maximum increase in AA
of 6.891.0 nA (n3; pB0.19) above baseline at
8.493.5 min following injection (see inset Fig. 4).
Using post in vivo calibrations this represents an in-
crease in AA concentration of 164923 mM represent-
ing an :30% increase in ECF levels assuming the
DPA technique causes minimum depletion as it is a fast
sampling technique (Lowry et al., 1997).
3.6. Stability of biosensor in 6i6o
The direct contact of biosensors with biological sam-
ples can lead to a decrease in sensitivity due to surface
fouling by proteins and other biomolecules. This de-
crease in sensitivity generally varies between 20 and
Fig. 4. The effect of intraperitoneal injection of ascorbic acid (AA; 2
ml, 2 g:kg) on the amperometric response of carbon paste (CPE; top)
and Pt:PPD:GOx (bottom) sensors implanted bilaterally in the stria-
tum of freely-moving rats. The CPEs monitored AA at a constant
potential of 250 mV. Data (n5) are normalised with the basal
level before injection taken as 100%. The hashed lines represent the
SEM which is plotted at 8 min intervals for clarity. Changes in
response expressed in nanoamperes of current are given in the text.
Inset: Example of the effect of a subanaesthetic injection of ketamine
(50 mg:kg, i.p.) on the CPE AA and Pt:PPD:GOx signals recorded
simultaneously in rat striatum. AA was monitored using differential
pulse amperometry. The baseline currents for both signals have been
subtracted. See Section 3.5.
50% and occurs over several hours exposure to brain
tissue (Garguilo and Michael, 1994; Hu et al., 1994).
Although previous in vitro studies have shown that
Pt:PPD:GOx sensors are virtually free from both
protein and lipid fouling (Lowry and O’Neill, 1994) we
carried out an additional in vitro conditioning of the
sensors prior to implantation (see Section 2.4), similar
to the preconditioning procedure used by Hill and
coworkers to improve the stability of ferrocene-medi-
ated glucose biosensors (Cass et al., 1984). The mean
baseline current recorded with preconditioned Pt:PPD:
GOx sensors implanted in the striatum of freely-moving
animals showed no significant variation (p\0.88, two-
way ANOVA; n6) over a successive 5 day period
from day 0 (ca. 1 h following recovery from surgical
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anaesthesia) to day 4: 15.693.5 nA (day 0); 16.292.2
nA (day 1); 16.193.6 nA (day 2); 14.092.7 nA (day 3)
and 13.292.4 nA (day 4). This represents a statistically
insignificant change in sensitivity after 5 days recording
and clearly demonstrates that the combination of non-
fouling properties of the PPD coating and in vitro
conditioning of the enzyme and Pt surface (via pro-
longed enzymatic turnover and H2O2 oxidation) ensures
minimal loss of sensitivity of these biosensors after
implantation and a resultant stable glucose signal in
vivo. Using glucose calibration data suggests that this
baseline level corresponds to a concentration of 4889
84 mM (n6).
4. Conclusions
These results demonstrate that our Pt:PPD:GOx sen-
sor responds to changing concentrations of glucose in
the extracellular compartment of the brain, is unaf-
fected by changes in the concentration of both O2 and
AA and is stable after implantation, clearly demon-
strating reliable glucose monitoring in vivo in freely-
moving animals.
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